To obtain the subject composition useful for treatment of cyclooxygenase-2 (COX-2)-mediated disease by including a specific compound and a carrier.

This pharmaceutical composition used for treatment of cyclooxygenase-2-mediated disease is obtained by formulating a therapeutically effective amount (10-250mg) of compound of the formula and a pharmaceutically acceptable carrier. The compound is used for treatment of inflammatory disease sensitive to the treatment with a non-steroidal anti-inflammatory drug, not chronic headache, pain or tumor, osteoarthropathy and chronic articular rheumatism by administrating 10-250mg, 60-120mg or 10-50mg to the patient requiring the treatment of these diseases. A administration form of the drug used for treatment of the before diseases is produced by using 10-250mg, 60-120mg or 10-50mg of the compound.